The Role of Congenital Mucosal Immune System in the Airways of Patients With Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to explore the role of congenital mucosal immune system in the airways of patients with COPD including the impact of ILCs (Innate lymphoid cells) on metabolism of epithelial cells.During the research the following methods will be applied: measurement of Volatile Organic Compounds (VOCS), airway epithelial cytology and culture.

Detailed Description
-----------------
ILCs profiles, epithelium metabolism measured by VOCS and microbiome profiling (specific 16S rRNA-16S ribosomal RNA gene-targeted qPCR) will by determined in the airways of patients with COPD after the exacerbation. Microbiome profiling will be based on next generation sequencing (NGS) of the 16S rRNA encoding region.

Official Title
-----------------
The Role of Congenital Mucosal Immune System in the Airways of Patients With COPD

Conditions
-----------------
COPD Exacerbation, Smoking, Tobacco

Intervention / Treatment
-----------------
* Diagnostic Test: airway epithelial smear test


Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria: Neoplasm Diabetes Astma acute airway infection in last 2 weeks
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| EX + / ECTS +<br>Patients suffering COPD exacerbation in last 7 days; active tobacco smokers | Diagnostic Test: airway epithelial smear test<br>* all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture<br>* Other names: culture;|
| EX - / ECTS +<br>Patients without COPD exacerbation in last 6 months; active tobacco smokers | Diagnostic Test: airway epithelial smear test<br>* all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture<br>* Other names: culture;|
| EX + / ECTS -<br>Patients suffering COPD exacerbation in last 7 days; quited tobacco smoking at least 12 months earlier | Diagnostic Test: airway epithelial smear test<br>* all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture<br>* Other names: culture;|
| EX - / ECTS -<br>Patients without COPD exacerbation in last 6 months; quited tobacco smoking at least 12 months earlier | Diagnostic Test: airway epithelial smear test<br>* all patients will be subjected to all scheduled procedures: airways epithelial smear test, measurement of VOCs in exhaled air and airways slide sample culture<br>* Other names: culture;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage of nasal ILCs (Innate lymphoid cells) after COPD exacerbation | The assessment of the nasal mucosa material after COPD exacerbation will include: percentage of ILC1, 2 and 3 cells (immunophenotyping and measurement by flow cytometry) | through study completion, an average of 1 year |